TQB3912 / Sino Biopharm - LARVOL DELTA

TQB3912-I-01: A Clinical Study of TQB3912 Tablets in Patients With Advanced Malignant Tumor (clinicaltrials.gov) - P1 | N=36 | Completed | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting ➔ Completed

Trial completion • Oncology • Solid Tumor

Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced or Metastatic Hormone Receptor(HR)-Positive and Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer (clinicaltrials.gov) - P1/2 | N=75 | Recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor

Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced or Metastatic Hormone Receptor(HR)-Positive and Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer (clinicaltrials.gov) - P1/2 | N=75 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

New P1/2 trial • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor

Zhengda Tianqing has a big explosion! It has won 11 blockbuster products, aggressively attacking the 220 billion market, and 80 Class 1 new drugs are on the way [Google translation] (Sina Corp) - "On November 25, Zhengda Tianqing's Class 1 new drug TQB2102 for injection received implicit approval for clinical trials. The drug, combined with endocrine drugs, is intended to be used for the treatment of HR-positive, HER2-low-expressing recurrent/metastatic breast cancer after CDK4/6 inhibitor resistance....On November 23, the IND applications for two Class 1 new drugs, TQB3720 tablets and TQB3912 tablets, of Zhengda Tianqing were accepted. Among them, TQB3720 tablets is an androgen receptor (AR) inhibitor used to treat prostate cancer; TQB3912 tablets is an AKT inhibitor used to treat breast cancer."

New trial • Breast Cancer • Genito-urinary Cancer • HER2 Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Prostate Cancer • Solid Tumor

Two new breast cancer drugs from Zhengda Tianqing approved for clinical trials [Google translation] (bydrug.pharmcube.com) - "On October 22, the official website of the Center for Drug Evaluation (CDE) of the China National Medical Products Administration announced that two Class 1 new drugs of Zhengda Tianqing have obtained implicit approval for clinical trials. The indications are TQB3616 capsules combined with TQB3912 tablets and Fulvestrant injection for the treatment of advanced HR-positive, HER2-negative breast cancer."

New trial • Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology

A Clinical Study of TQB3912 Tablets in Patients With Advanced Malignant Tumor (clinicaltrials.gov) - P1 | N=88 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Metastases • New P1 trial • Oncology • Solid Tumor